Metraipolis › archive › dc_9ebdc990fb66

Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes — Europe PMC PMID:41303213

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41303213
DOI
10.3390/jcm14228179
License (as archived)
solo-consultazione
Archived
2026-11-08T11:33:21.150Z
SHA-256 of the archived text
f509028cdd710cd8237b046fe7b3d959da7d85cd7468c72e9179764a495a0d82
Stable URL of this page
https://metraipolis.com/documento/dc_9ebdc990fb66

How to cite

Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes — Europe PMC PMID:41303213 — Europe PMC (en), https://europepmc.org/article/MED/41303213 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9ebdc990fb66 (Metraipolis archive dc_9ebdc990fb66, sha256 f509028cdd710cd8237b046fe7b3d959da7d85cd7468c72e9179764a495a0d82)
BibTeX
@misc{dc9ebdc990fb66,
  title = {Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes — Europe PMC PMID:41303213},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41303213},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9ebdc990fb66; sha256 f509028cdd710cd8237b046fe7b3d959da7d85cd7468c72e9179764a495a0d82},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41303213. Agents can read the archived copy with the MCP tool read_document.